A first patient has been dosed in Scotland as part of Molecure’s Phase 2 clinical trial — taking place in the U.S. and Europe — that will test the pulmonary sarcoidosis treatment candidate OATD-01 versus a placebo. “The first administration to a patient with pulmonary sarcoidosis is the realization…
News
Saying “sarcoidosis” can be problematic for some, so the Foundation for Sarcoidosis Research (FSR) will focus on the condition’s pronunciation as part of this year’s National Sarcoidosis Awareness Month, which is observed each April. Sarcoidosis is also difficult to diagnose, and therapies can only manage its symptoms.
A test that detects disease-specific antibodies in the blood could help to diagnose sarcoidosis more quickly and easily, according to a recent study. “More testing needs to be completed before this screening method is ready for clinical use, but it’s possible that could be a reality within a few…
Acthar Gel (repository corticotropin injection) treats African Americans with sarcoidosis as effectively as it does patients of other races, a study suggests. The study, “Acthar Gel in African Americans versus Non-African Americans with Symptomatic Sarcoidosis: Physician Assessment of Patient Medical Records,” was published in Therapeutics…
Nearly a quarter of sarcoidosis patients were found to have clinically silent cardiac involvement, in which standard heart symptoms are not observed, recent research indicated. Readily available cardiac screening tools, when used in combination, may help to rule out the presence of this hidden disease manifestation and avoid…
To help boost awareness of sarcoidosis and support those affected by the complex and often misunderstood disorder, the Foundation for Sarcoidosis Research (FSR) is hosting its first in-person training of its Global Sarcoidosis Clinic Alliance (FSR-GSCA) volunteer patient leaders at the Cleveland Clinic. The training takes place…
Scientists at the University of Colorado are planning a study to better classify sarcoidosis as it affects the eyes, called ocular sarcoidosis. Having a grasp on the specific biological mechanisms that drive sarcoidosis in different patients could lead to more targeted treatments, researchers say. “Improving our ability to define…
People with sarcoidosis are significantly more likely to develop venous thromboembolism (VTE), which occurs when a blood clot forms in a vein, over 10 years than the general population, a nationwide study in Denmark suggests. And while there are substantial differences in clinical characteristics between those who develop VTE…
The percentage of natural killer (NK) immune cells in the airways were predictive of a more advanced stage of lung damage and multi-organ involvement in people with pulmonary sarcoidosis, according to a recent report. Altogether, the scientists believe these cells could be “a good prognostic marker” of a more…
Elevated blood levels of total blood cholesterol and low levels of high density lipoprotein cholesterol (HDL) — commonly called the “good” cholesterol — showed a significant correlation with sarcoidosis, according to a retrospective study conducted in China. These findings suggest HDL and total blood cholesterol “could be regarded as…
Recent Posts
- New AI model predicts sudden cardiac death risk better in cardiac sarcoidosis
- FSR invests $400K in 4 early-stage sarcoidosis research projects
- The questions of menopause mirror the uncertainty of sarcoidosis
- 7 new institutions join FSR alliance to improve treatment of sarcoidosis
- Simple blood test may predict cardiac sarcoidosis outcomes
- To scoot or not to scoot: Using a mobility aid with a dynamic disability
- Mobile app for breathing meditation may reduce sarcoidosis fatigue
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF